What is iFyber?
iFyber operates as a sophisticated preclinical contract research organization that bridges the gap between chemistry, biology, and materials science. The company provides a comprehensive suite of analytical services, including microbial control, biofilm testing, and antimicrobial efficacy validation. By catering to high-stakes industries such as medical devices, wound care, and diagnostics, iFyber serves as a critical partner for firms requiring rigorous scientific validation and custom method development. Their unique value proposition lies in their ability to provide personalized, expert-led research support that helps clients navigate complex regulatory and development hurdles in the life sciences and specialty textiles markets.
How much funding has iFyber raised?
iFyber has raised a total of $378K across 2 funding rounds:
Debt
$150K
Debt
$228K
Debt (2020): $150K with participation from PPP
Debt (2021): $228K led by PPP
Key Investors in iFyber
PPP
Public-Private Partnership
Undisclosed Investor
An institutional participant providing strategic financing to facilitate long-term research and development initiatives.
Undisclosed Investor
A private capital provider specializing in supporting the expansion of specialized contract research organizations.
What's next for iFyber?
With the recent infusion of capital, iFyber is poised to scale its operational infrastructure to meet the increasing demand for specialized antimicrobial and materials testing. The company is expected to focus on enhancing its laboratory capacity and expanding its technical team to support larger-scale projects for its diverse client base. As the firm transitions through this late-stage growth phase, the strategic deployment of these funds will likely prioritize the integration of advanced analytical technologies and the expansion of its service portfolio, ensuring that iFyber remains at the forefront of preclinical innovation and scientific excellence in the medical and materials sectors.
See full iFyber company page
